356 related articles for article (PubMed ID: 33512666)
1. Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial.
Papp KA; de Vente S; Zeng J; Flack M; Padilla B; Tyring SK
Dermatol Ther (Heidelb); 2021 Apr; 11(2):487-497. PubMed ID: 33512666
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
Blauvelt A; Leonardi CL; Gooderham M; Papp KA; Philipp S; Wu JJ; Igarashi A; Flack M; Geng Z; Wu T; Camez A; Williams D; Langley RG
JAMA Dermatol; 2020 Jun; 156(6):649-658. PubMed ID: 32267471
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
Crowley JJ; Langley RG; Gordon KB; Pinter A; Ferris LK; Rubant S; Photowala H; Xue Z; Wu T; Zhan T; Beeck S; Shah M; Warren RB
Dermatol Ther (Heidelb); 2022 Feb; 12(2):561-575. PubMed ID: 35050485
[TBL] [Abstract][Full Text] [Related]
5. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
Reich K; Gooderham M; Thaçi D; Crowley JJ; Ryan C; Krueger JG; Tsai TF; Flack M; Gu Y; Williams DA; Thompson EHZ; Paul C
Lancet; 2019 Aug; 394(10198):576-586. PubMed ID: 31280967
[TBL] [Abstract][Full Text] [Related]
6. Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).
Stein Gold LF; Bagel J; Tyring SK; Hong HC; Pavlovsky L; Vender R; Pinter A; Reich A; Drogaris L; Wu T; Patel M; Soliman AM; Photowala H; Stakias V; Richter S; Papp KA
Br J Dermatol; 2023 Oct; 189(5):540-552. PubMed ID: 37488811
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up.
Papp KA; Blauvelt A; Puig L; Ohtsuki M; Beissert S; Gooderham M; Amin AZ; Liu J; Wu T; Azam T; Stakias V; Espaillat R; Sinvhal R; Soliman AM; Pang Y; Chen MM; Lebwohl MG
J Am Acad Dermatol; 2023 Dec; 89(6):1149-1158. PubMed ID: 37553030
[TBL] [Abstract][Full Text] [Related]
8. Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal.
Al-Janabi A; Jabbar-Lopez ZK; Griffiths CEM; Yiu ZZN
Br J Dermatol; 2019 Jun; 180(6):1348-1351. PubMed ID: 30632140
[TBL] [Abstract][Full Text] [Related]
9. Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation.
Odnopozova L; Edin A; Sukharev A; Wu T; Aydin K; Kelly M; Khotko A
Dermatol Ther (Heidelb); 2022 Sep; 12(9):2063-2075. PubMed ID: 35917057
[TBL] [Abstract][Full Text] [Related]
10. Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.
Augustin M; Lambert J; Zema C; Thompson EHZ; Yang M; Wu EQ; Garcia-Horton V; Geng Z; Valdes JM; Joshi A; Gordon KB
JAMA Dermatol; 2020 Dec; 156(12):1344-1353. PubMed ID: 33052382
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up.
Papp KA; Lebwohl MG; Puig L; Ohtsuki M; Beissert S; Zeng J; Rubant S; Sinvhal R; Zhao Y; Soliman AM; Alperovich G; Leonardi C
Br J Dermatol; 2021 Dec; 185(6):1135-1145. PubMed ID: 34157132
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial.
Warren RB; Blauvelt A; Poulin Y; Beeck S; Kelly M; Wu T; Geng Z; Paul C
Br J Dermatol; 2021 Jan; 184(1):50-59. PubMed ID: 32594522
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial.
Ohtsuki M; Fujita H; Watanabe M; Suzaki K; Flack M; Huang X; Kitamura S; Valdes J; Igarashi A
J Dermatol; 2019 Aug; 46(8):686-694. PubMed ID: 31237727
[TBL] [Abstract][Full Text] [Related]
14. Exposure-Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis.
Suleiman AA; Khatri A; Oberoi RK; Othman AA
Clin Pharmacokinet; 2020 May; 59(5):575-589. PubMed ID: 31667790
[TBL] [Abstract][Full Text] [Related]
15. Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis.
Gooderham M; Pinter A; Ferris LK; Warren RB; Zhan T; Zeng J; Soliman AM; Kaufmann C; Kaplan B; Photowala H; Strober B
J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):855-865. PubMed ID: 35174556
[TBL] [Abstract][Full Text] [Related]
16. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Spuls PI; Hooft L
Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
[TBL] [Abstract][Full Text] [Related]
17. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
Papp KA; Blauvelt A; Bukhalo M; Gooderham M; Krueger JG; Lacour JP; Menter A; Philipp S; Sofen H; Tyring S; Berner BR; Visvanathan S; Pamulapati C; Bennett N; Flack M; Scholl P; Padula SJ
N Engl J Med; 2017 Apr; 376(16):1551-1560. PubMed ID: 28423301
[TBL] [Abstract][Full Text] [Related]
18. Direct comparison of risankizumab and fumaric acid esters in systemic therapy-naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial.
Thaçi D; Eyerich K; Pinter A; Sebastian M; Unnebrink K; Rubant S; Williams DA; Weisenseel P
Br J Dermatol; 2022 Jan; 186(1):30-39. PubMed ID: 33991341
[TBL] [Abstract][Full Text] [Related]
19. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
Feagan BG; Panés J; Ferrante M; Kaser A; D'Haens GR; Sandborn WJ; Louis E; Neurath MF; Franchimont D; Dewit O; Seidler U; Kim KJ; Selinger C; Padula SJ; Herichova I; Robinson AM; Wallace K; Zhao J; Minocha M; Othman AA; Soaita A; Visvanathan S; Hall DB; Böcher WO
Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):671-680. PubMed ID: 30056030
[TBL] [Abstract][Full Text] [Related]
20. Meta-Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority.
Witjes H; Khatri A; Diderichsen PM; Mandema J; Othman AA
Clin Pharmacol Ther; 2020 Feb; 107(2):435-442. PubMed ID: 31502263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
